Kidney Transplant Rejection Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, Regulatory Updates by DelveInsight | Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor Therapeutics, Talaris Therapeutics, C

DelveInsight's "Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Kidney Transplant Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Kidney Transplant Rejection Market Forecast
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Kidney Transplant Rejection Market Report:
• The Kidney Transplant Rejection market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2024, Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) has released updated findings from its continuing open-label Phase 1b trial and open-label extension study investigating tegoprubart's efficacy in preventing organ rejection in kidney transplant recipients. The results, presented at the American Transplant Congress (ATC) held in Philadelphia, were outlined in a poster titled "Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transplant."
• In May 2024, Human Immunology Biosciences (HI-Bio™), a biotechnology company in the clinical stage, dedicated to developing precise treatments for individuals with severe immune-mediated diseases (IMDs), has unveiled encouraging outcomes from a Phase 2 clinical trial initiated by investigators, evaluating felzartamab for late antibody-mediated rejection (AMR) in kidney transplant patients.
• In September 2023, Eledon Pharmaceuticals initiated dosing for the initial participant in the Phase II BESTOW trial, focusing on tegoprubart's role in preventing organ rejection following kidney transplantation. This multicenter study, employing an active comparator with two arms, aims to evaluate the pharmacokinetics, efficacy, and safety of tegoprubart, an anti-CD40 ligand antibody, compared to the calcineurin inhibitor tacrolimus.
• In a research involving 22,730 kidney recipients in the UK, 23.7% (5,389) of the transplanted kidneys experienced graft failure over a median follow-up period of 5 years. The primary reasons for graft failure were death with a functioning graft (40.8%) and alloimmune pathology (25.0%) as reported by Burton et al. in 2018.
• Key Kidney Transplant Rejection Companies: Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others
• Key Kidney Transplant Rejection Therapies: MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 - MMF - CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others
• The Kidney Transplant Rejection epidemiology based on gender analyzed that there is no gender-based difference; however, older individuals have a higher incidence of kidney transplant rejection than young individuals.
• The Kidney Transplant Rejection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Kidney Transplant Rejection pipeline products will significantly revolutionize the Kidney Transplant Rejection market dynamics.

Kidney Transplant Rejection Overview
Kidney transplant rejection occurs when the recipient's immune system recognizes the transplanted kidney as foreign and attacks it. This immune response can lead to damage and dysfunction of the transplanted kidney, ultimately compromising its function.

Get a Free sample for the Kidney Transplant Rejection Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Kidney Transplant Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Kidney Transplant Rejection Epidemiology Segmentation:
The Kidney Transplant Rejection market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Kidney Transplant Rejection
• Prevalent Cases of Kidney Transplant Rejection by severity
• Gender-specific Prevalence of Kidney Transplant Rejection
• Diagnosed Cases of Episodic and Chronic Kidney Transplant Rejection

Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Epidemiology Forecast
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Kidney Transplant Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Kidney Transplant Rejection market or expected to get launched during the study period. The analysis covers Kidney Transplant Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Kidney Transplant Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Kidney Transplant Rejection Therapies and Key Companies
• MDR-101: Medeor Therapeutics
• MDR-102: Medeor Therapeutics
• FCR001: Talaris Therapeutics
• Clazakizumab: CSL Behring
• Tegoprubart: Eledon Pharmaceuticals
• Sonazoid: GE Healthcare
• Belatacept: Viela Bio
• AT-1501: Eledon Pharmaceuticals
• Simulect: Neovii Biotech
• belimumab: GlaxoSmithKline
• CFZ533 - MMF - CS: Novartis
• Imlifidase: Hansa Biopharma AB
• tacrolimus: Astellas Pharma Inc
• BIVV020 (SAR445088): Sanofi
• Cyclosporine: Bristol-Myers Squibb

Discover more about therapies set to grab major Kidney Transplant Rejection market share @ Kidney Transplant Rejection Treatment Landscape
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Kidney Transplant Rejection Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Kidney Transplant Rejection Companies: Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others
• Key Kidney Transplant Rejection Therapies: MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 - MMF - CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others
• Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
• Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Kidney Transplant Rejection Unmet Needs, KOL's views, Analyst's views, Kidney Transplant Rejection Market Access and Reimbursement

To know more about Kidney Transplant Rejection companies working in the treatment market, visit @ Kidney Transplant Rejection Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Kidney Transplant Rejection Market Report Introduction
2. Executive Summary for Kidney Transplant Rejection
3. SWOT analysis of Kidney Transplant Rejection
4. Kidney Transplant Rejection Patient Share (%) Overview at a Glance
5. Kidney Transplant Rejection Market Overview at a Glance
6. Kidney Transplant Rejection Disease Background and Overview
7. Kidney Transplant Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Kidney Transplant Rejection
9. Kidney Transplant Rejection Current Treatment and Medical Practices
10. Kidney Transplant Rejection Unmet Needs
11. Kidney Transplant Rejection Emerging Therapies
12. Kidney Transplant Rejection Market Outlook
13. Country-Wise Kidney Transplant Rejection Market Analysis (2019-2032)
14. Kidney Transplant Rejection Market Access and Reimbursement of Therapies
15. Kidney Transplant Rejection Market Drivers
16. Kidney Transplant Rejection Market Barriers
17. Kidney Transplant Rejection Appendix
18. Kidney Transplant Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Kidney Transplant Rejection Pipeline https://www.delveinsight.com/report-store/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Kidney Transplant Rejection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Kidney Transplant Rejection market. A detailed picture of the Kidney Transplant Rejection pipeline landscape is provided, which includes the disease overview and Kidney Transplant Rejection treatment guidelines.
Kidney Transplant Rejection Epidemiology https://www.delveinsight.com/report-store/kidney-transplant-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Kidney Transplant Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Kidney Transplant Rejection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Graft Versus Host Disease Market http://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft-versus-host Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Graft-versus-host Disease, historical and forecasted epidemiology as well as the Graft-versus-host Disease market trends in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Implantable Cardioverter Defibrillators Market http://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
DelveInsight's 'Implantable Cardioverter Defibrillators (ICDs) - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Implantable Cardioverter Defibrillators (ICDs) and the historical and forecasted Implantable Cardioverter Defibrillators (ICDs) market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.